Estrella Immunopharma, Inc. (ESLAW) Risk Assessment & Volatility Analysis

Comprehensive risk assessment and volatility analysis for ESLAW including beta analysis, market risk, financial risk, and investment risk evaluation. Understand the potential risks and rewards of investing in ESLAW stock with expert risk management insights.

Risk Assessment Summary

Low overall risk profile

Low market volatility (Beta < 0.8)

Governance Risk

Overall Risk Score

N/A

Audit Risk

N/A

Board Risk

N/A

Compensation Risk

N/A

Shareholder Rights Risk

N/A

Market Risk

Beta (5Y Monthly)

-0.09Low

52-Week Change

N/A

S&P 500 52-Week Change

12.66%Very High

Short Interest Ratio

N/A

Short % of Float

N/A

Volatility (Annualized)

N/A

Financial Risk

Total Debt

$22.00K

Enterprise Value

N/A

Profit Margins

0.00%Very High

Earnings Growth (QoQ)

N/A

Net Income to Common

$-11114402.00

Book Value

$-2.89

Risk vs Reward Analysis

Risk Factors

Beta: -0.09

Volatility: N/A

Short Interest: N/A

Potential Rewards

52-Week Change: N/A

Earnings Growth: N/A

Profit Margin: 0.00%